Zevra Therapeutics (NASDAQ:ZVRA) Upgraded by Cantor Fitzgerald to Strong-Buy Rating

Zevra Therapeutics (NASDAQ:ZVRA) was upgraded by Cantor Fitzgerald to a “strong-buy” rating in a research report issued on Wednesday,Zacks.com reports.

ZVRA has been the topic of several other reports. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Guggenheim initiated coverage on shares of Zevra Therapeutics in a research report on Monday, October 7th. They issued a “buy” rating and a $20.00 price target on the stock. Finally, Canaccord Genuity Group reduced their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $21.57.

Zevra Therapeutics Stock Performance

Shares of ZVRA opened at $7.86 on Wednesday. The company has a market capitalization of $419.57 million, a PE ratio of -3.99 and a beta of 2.01. Zevra Therapeutics has a one year low of $4.20 and a one year high of $9.76. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The company’s fifty day moving average price is $8.58 and its 200 day moving average price is $7.92.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The company had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.04 million. During the same quarter in the previous year, the firm posted ($0.40) EPS. As a group, analysts expect that Zevra Therapeutics will post -1.95 earnings per share for the current year.

Institutional Investors Weigh In On Zevra Therapeutics

Large investors have recently bought and sold shares of the company. Vestal Point Capital LP bought a new stake in shares of Zevra Therapeutics during the third quarter worth $3,644,000. Sanctuary Advisors LLC bought a new stake in shares of Zevra Therapeutics during the second quarter worth $474,000. Geode Capital Management LLC increased its position in shares of Zevra Therapeutics by 14.2% during the third quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock worth $7,246,000 after acquiring an additional 129,600 shares in the last quarter. Propel Bio Management LLC bought a new stake in shares of Zevra Therapeutics during the third quarter worth $1,248,000. Finally, Barclays PLC increased its position in shares of Zevra Therapeutics by 292.6% during the third quarter. Barclays PLC now owns 57,599 shares of the company’s stock worth $399,000 after acquiring an additional 42,926 shares in the last quarter. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.